RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study

Core Insights - Recursion Pharmaceuticals (RXRX) has initiated dosing for the first patient in its early-stage study of REC-3565, aimed at treating relapsed or refractory B-cell lymphomas, utilizing its AI-driven Recursion OS platform [1][2] - The unique mechanism of REC-3565 is anticipated to reduce the risk of drug-drug interactions and hyperbilirubinemia, potentially allowing for safer dose escalation and improved clinical efficacy [2] - RXRX's shares have decreased by 41.3% year-to-date, contrasting with a 14.6% decline in the industry [3] Pipeline Development - The Phase I EXCELERIZE study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of REC-3565, structured in two parts: monotherapy and combination therapy [5] - REC-3565 is positioned to address the limited treatment options available for relapsed or refractory B-cell lymphomas, with the potential to enhance patient outcomes [6] Other Pipeline Candidates - RXRX is also developing REC-994 for cerebral cavernous malformation (CCM), affecting approximately 360,000 symptomatic individuals in the US and EU, with a broader global impact potentially exceeding one million patients [7] - The company has met primary safety endpoints in mid-stage studies for REC-994 and plans to consult with the FDA for further development pathways [8] - Other mid-stage candidates include REC-2282 (neurofibromatosis type II), REC-4881 (familial adenomatous polyposis), REC-3964 (recurrent Clostridioides difficile infection), and REC-1245 (biomarker-enriched solid tumors and lymphoma) [9] Collaborations - RXRX has established collaboration agreements with major pharmaceutical companies such as Roche, Bayer, Merck, and Sanofi to develop candidates for various oncology indications [10]